Eton Pharmaceuticals, INC

Eton Pharmaceuticals, Inc. announced the appointment of Danka Radosavljevic as Chief Operating Officer, effective July 31, 2026.

Eton Pharmaceuticals announced the submission of a Prior Approval Supplement to the FDA to expand the indication of KHINDIVI (hydrocortisone) oral solution to younger pediatric patients.

Eton Pharmaceuticals, Inc. held its 2026 Annual Meeting of Stockholders, where directors were elected and the appointment of its independent auditor was ratified.

Eton Pharmaceuticals has secured exclusive U.S. commercialization rights for IMPAVIDO (miltefosine), an FDA-approved oral therapy for leishmaniasis, expanding its rare disease portfolio.

Eton Pharmaceuticals announced the first patient dosed in a pilot study for ET-700, an extended-release zinc acetate formulation for Wilson disease, with topline results expected in late 2026.

Eton Pharmaceuticals has appointed Judith M. Matthews as the new Chief Financial Officer, effective June 1, 2026.

Eton Pharmaceuticals, Inc. announced its first quarter 2026 financial results, showing a significant increase in net revenues and a return to profitability.

Eton Pharmaceuticals, Inc. reported significant revenue growth and a substantial increase in cash from operating activities for the nine months ended September 30, 2025, driven by new product sales and licensing deals, despite a larger net loss.

Eton Pharmaceuticals reported a significant increase in total net revenues and gross profit for the first half of 2025, driven by new product acquisitions and licensing deals, alongside a positive shift in cash flow from operations.

Eton Pharmaceuticals saw a significant increase in total revenue and gross profit for the first quarter of 2025, driven by product sales and licensing agreements.

Eton Pharmaceuticals saw revenue growth in Q3 2024, primarily driven by increased product sales and royalties, alongside the launch of new products.

Eton Pharmaceuticals' second quarter 2024 results show a decrease in total revenue compared to the same period last year, primarily due to a prior sale of royalty interests, though product sales have increased.

Eton Pharmaceuticals reports significant revenue growth in 2025 driven by product sales, despite an increased net loss and ongoing R&D investments.

Eton Pharmaceuticals' 10-K filing reveals a year of revenue growth and strategic acquisitions, alongside a necessary accounting adjustment for the INCRELEX acquisition.

Eton Pharmaceuticals has filed an amendment to its annual report to correct the consent of its independent accounting firm, with no other changes to the original filing.

Eton Pharmaceuticals has adopted a clawback policy to recoup executive incentive compensation in the event of an accounting restatement due to material noncompliance with financial reporting requirements.

Opaleye Management Inc. reported changes in beneficial ownership of Eton Pharmaceuticals, Inc. common stock on July 14, 2026.

Opaleye Management Inc. reported changes in beneficial ownership of Eton Pharmaceuticals, Inc. common stock on July 14, 2026.

Sean Brynjelsen, President & CEO and a Director of Eton Pharmaceuticals, Inc., reported multiple transactions in common stock on July 12, 2026.

David Krempa, Chief Business Officer of Eton Pharmaceuticals, Inc., reported multiple transactions in common stock on July 12, 2026.

Opaleye Management Inc. reported significant sales of Eton Pharmaceuticals Inc. common stock between July 2nd and July 7th, 2026.

Eton Pharmaceuticals Chief Business Officer David Krempa was granted 10,000 restricted stock units, vesting over four years.

Eton Pharmaceuticals will hold its 2025 Annual Meeting of Stockholders virtually on June 10, 2025, to elect a director, ratify the appointment of its accounting firm, and transact other business.

Eton Pharmaceuticals announces its 2024 Annual Meeting of Stockholders to be held virtually on June 11, 2024, to vote on director elections, executive compensation, auditor ratification, and other business.

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Eton Pharmaceuticals Inc. following an internal realignment.

The Vanguard Group has reported a 5.01% beneficial ownership stake in Eton Pharmaceuticals Inc., holding over 1.3 million shares.

BlackRock, Inc. has filed a Schedule 13G, reporting beneficial ownership of 5.7% of Eton Pharmaceuticals, Inc.'s Common Stock as of June 30, 2025.

EcoR1 Capital, LLC and its affiliates, including Oleg Nodelman, have disclosed a 7.7% beneficial ownership stake in Eton Pharmaceuticals, Inc. as of December 31, 2024, held for investment purposes.